DualityBio, BioNTech Expand Partnership for Solid Tumor Antibody-Drug Conjugate

08 August 2023 | Tuesday | News

Duality Biologics (Suzhou) Co. Ltd. ("DualityBio"), a clinical-stage biotech company focusing on the discovery and development of next generation antibody-drug conjugate ("ADC") therapeutics to treat patients with cancer and autoimmune diseases, announced that the company has expanded its collaboration with BioNTech SE to develop, manufacture and commercialize a third ADC candidate DB-1305 globally, excluding Mainland China, Hong Kong Special Administrative Region and Macau Special Administrative Region. DB-1305 is currently in a Phase 1/2 clinical trial (NCT05438329) for solid tumors.

Image Source : Public Domain

The agreement further builds upon the strategic collaboration the companies announced in April 2023.

Under the terms of the agreements, DualityBio will receive upfront payments, additional development, regulatory and commercial milestone payments, and single-digit to low-double digit tiered royalties on net sales of DB-1305. BioNTech will hold commercial rights globally (excluding Mainland China, Hong Kong Special Administrative Region and Macau Special Administrative Region), while DualityBio will retain commercial rights for Mainland China, Hong Kong Special Administrative Region and Macau Special Administrative Region.

DualityBio, BioNTech Expand Partnership for Solid Tumor Antibody-Drug Conjugate

Stay Connected